[{"orgOrder":0,"company":"Northway Biotechpharma","sponsor":"Memo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"LITHUANIA","productType":"Large molecule","year":"2020","type":"Partnership","leadProduct":"MTX-COVAB","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Northway Biotechpharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Northway Biotechpharma \/ Memo Therapeutics AG","highestDevelopmentStatusID":"2","companyTruncated":"Northway Biotechpharma \/ Memo Therapeutics AG"},{"orgOrder":0,"company":"Northway Biotechpharma","sponsor":"Revolo Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"LITHUANIA","productType":"Large molecule","year":"2021","type":"Agreement","leadProduct":"\u20181805","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Northway Biotechpharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Northway Biotechpharma \/ Revolo Biotherapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Northway Biotechpharma \/ Revolo Biotherapeutics"},{"orgOrder":0,"company":"Northway Biotechpharma","sponsor":"Immutep","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"LITHUANIA","productType":"Large molecule","year":"2021","type":"Agreement","leadProduct":"IMP761","moa":"LAG-3","graph1":"Immunology","graph2":"Preclinical","graph3":"Northway Biotechpharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Northway Biotechpharma \/ Immutep","highestDevelopmentStatusID":"4","companyTruncated":"Northway Biotechpharma \/ Immutep"},{"orgOrder":0,"company":"Northway Biotechpharma","sponsor":"iTolerance","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"LITHUANIA","productType":"Cell and Gene therapy","year":"2023","type":"Partnership","leadProduct":"iTOL-102","moa":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Northway Biotechpharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Northway Biotechpharma \/ iTolerance","highestDevelopmentStatusID":"4","companyTruncated":"Northway Biotechpharma \/ iTolerance"},{"orgOrder":0,"company":"Northway Biotechpharma","sponsor":"Mallia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"LITHUANIA","productType":"Protein","year":"2025","type":"Partnership","leadProduct":"Undisclosed","moa":"CD38","graph1":"Dermatology","graph2":"Preclinical","graph3":"Northway Biotechpharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Northway Biotechpharma \/ Mallia Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Northway Biotechpharma \/ Mallia Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals by Northway Biotechpharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The Generic Rx Session
                          Not Confirmed
                          The Generic Rx Session
                          Not Confirmed

                          Details : Through the partnership, Northway Biotech will leverage its expertise in biologics manufacturing to develop the production process for the recombinant sCD83 protein for Hair loss treatment.

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Undisclosed

                          February 04, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Dermatology

                          Highest Development Status : Preclinical

                          Sponsor : Mallia Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          02

                          The Generic Rx Session
                          Not Confirmed
                          The Generic Rx Session
                          Not Confirmed

                          Details : The agreement aims for the commercialising of Folotyn (Pralatrexate), a dihydrofolate reductase inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma, in the People's Republic of China.

                          Product Name : iTOL-102

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          August 01, 2023

                          Lead Product(s) : iTOL-102

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Preclinical

                          Sponsor : iTolerance

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          03

                          The Generic Rx Session
                          Not Confirmed
                          The Generic Rx Session
                          Not Confirmed

                          Details : Under the agreement, Northway has already started developing a GMP-compliant manufacturing process of IMP761 and will manufacture IMP761 in large scale bioreactors. Planning for further pre-clinical and clinical development is ongoing.

                          Product Name : IMP761

                          Product Type : Large molecule

                          Upfront Cash : Undisclosed

                          December 16, 2021

                          Lead Product(s) : IMP761

                          Therapeutic Area : Immunology

                          Highest Development Status : Preclinical

                          Sponsor : Immutep

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          04

                          PharmScience R&D
                          Not Confirmed
                          PharmScience R&D
                          Not Confirmed

                          Details : Under the terms of the agreement, Northway will provide the full scope of its’ services ranging from cell line development to batch production of ‘1805 Active Pharmaceutical Ingredients (API) and drug product, following Current Good Manufacturing Pra...

                          Product Name : IRL201805

                          Product Type : Large molecule

                          Upfront Cash : Undisclosed

                          June 09, 2021

                          Lead Product(s) : ‘1805

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Revolo Biotherapeutics

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          05

                          The Generic Rx Session
                          Not Confirmed
                          The Generic Rx Session
                          Not Confirmed

                          Details : Under the terms of the agreement, Northway will develop the cell line and the manufacturing process, and will further produce cGMP batches of MTx´s antibody for clinical studies and will also execute commercial production once MTX-COVAB receives marketi...

                          Product Name : MTX-COVAB

                          Product Type : Large molecule

                          Upfront Cash : Undisclosed

                          August 14, 2020

                          Lead Product(s) : MTX-COVAB

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Discovery

                          Sponsor : Memo Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank